ArticleParasites & vectors2026
Evaluating the effect of immunization with DNA encoding Phlebotomus sergenti apyrase protein (PsSP42) against Leishmania tropica infection in BALB/c mouse model.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLeishmania parasites are transmitted through the bite of infected female sand flies. The sand fly inoculum contains both the parasite and the salivary proteins, which can modulate the immune system's function. Some of these salivary proteins have the potential to be used as a vaccine candidate. Since there have been fewer studies investigating the salivary proteins of Phlebotomus (Ph.) sergenti, this prompted us to select among the three protein members of Ph. sergenti apyrase family (PsSP40, PsSP41, and PsSP42) and measure its effectiveness as vaccine candidate against Leishmania (L.) tropica.
methodsTo select among the three family members as the candidate for immunization, different parameters including the physicochemical characters, three-dimensional structure, virtual immune stimulatory potential, and human leukocyte antigen (HLA) class II-binding epitope content were considered. To investigate the effect of immunization with the selected antigen through immunoinformatics analysis (PsSP42) against L. tropica infection, we immunized BALB/c mice with two distinct recombinant plasmids (conventional VR1020 and new-generation NTC9385R) two times at 3-week intervals followed by immediate electroporation. Eight weeks post-challenge, the parasite load in draining lymph nodes was measured by quantitative real-time polymerase chain reaction (PCR). The interferon (IFN)-γ and interleukin (IL)-4 cytokines before (against recombinant Leishmania tarentolae expressing PsSP42) and after (against parasite frozen/thawed antigens) L. tropica infection (2 × 10
resultsOn the basis of immunoinformatics analysis of three apyrase salivary proteins from Ph. sergenti, PsSP42 demonstrated superior HLA class II-binding peptides compared with the other two proteins (PsSP40 and PsSP41) and was selected for immunization studies. Our findings indicated that NTC-PsSP42 and not VR1020-PsSP42 plasmid immunization relatively reduced the parasite load in the draining lymph nodes. This was assigned to a significant higher IFN-γ to IL-4 ratio induced by NTC-PsSP42 immunization in comparison with pertinent controls.
conclusionsIn our study, although the expected protective response was not achieved by any of the recombinant plasmids, the NTC-PsSP42 platform induced a weak Th1-polarized immune response, which partially influenced the parasite load. Since the new generation of plasmids are worth evaluating owing to the lack of antibiotic resistance genes on the backbone, we recommend further assessment of NTC-PsSP42 potential adjuvnated with immunostimulatory sequences such as as CpG motifs or even in heterologous prime-boost regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.